Karl and Erum sit down with Massimo Portincaso, founder of Arsenale BioYards, to discuss the urgent need to rethink how we scale biomanufacturing. Massimo shares why today’s approach to industrial biotech—modeled after biopharma—is fundamentally flawed and how Arsenale is flipping the script. From nature co-design to AI-driven strain selection, he lays out a bold vision for scaling bio-based production in a way that is economically viable and industrially scalable. If you care about the future of precision fermentation, sustainable materials, and the bioeconomy, this is a conversation you don’t want to miss!Learn more at www.messaginglab.com/groweverythingLinks and Resources:Arsenale BioyardsFarm.OneCommon Side Effects (TV series)Nature Co-Design reportGenomatica aka GenoOfficinae Bio (now Maravai Life Sciences)"Scaling Cells, Dreaming Big: The Biomanufacturing Cloud with Synonym’s Edward Shenderovich" Topics Covered: Biomanufacturing, bioreactors, downstream processing, upstream processing, bioengineering, bioeconomy, italian biotech Have a question or comment? Message us here:Text or Call (804) 505-5553Instagram / Twitter / LinkedIn / Youtube / Grow EverythingEmail: [email protected] by: NihiloreProduction by: Amplafy Media

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related